1342.5 - Oncotype DX breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (Resubmission)

Page last updated: 01 April 2019

Application Detail

Status

Open

Description of Medical Service

Oncotype DX is a genomic test that predicts likelihood of response to adjuvant chemotherapy and 10-year cancer recurrence in patients with node-negative and node positive (1–3), oestrogen-receptor-positive(ER+), human epidermal growth factor receptor 2 negative(HER2-), invasive breast cancer.

Description of Medical Condition

Outside Australia, Oncotype DX is currently used in women with node-negative and node positive (1-3), oestrogen-receptor-positive, HER2 negative invasive early stage breast cancer.

Reason for Application

Re-submission

Medical Service Type

Investigative

Previous Application Numbers

1342
1342.1
1342.2
1342.3
1342.4

Associated Documentation

Application Form

-

Consultation Survey

Feedback and comments are welcome at any stage during the MSAC process. Please provide comments on Application 1342.5 via a maximum of two A4 pages to HTA@health.gov.au (making sure that you type the application number at the start of your comments and in the subject heading of your email).

PICO Confirmation

As per application 1342

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

-

ESC

13 June 2019

MSAC

-